There are errors in the Funding section. The correct funding information is as follows: This work was funded by the Amsterdam Brain and Cognition priority program; grant number: ABC2014-01 (http://abc.uva.nl/research/nav), the European Union 7th Framework Programme (FP7/2007-2013) under grant agreement no. 604102 (Human Brain Project; http://www.humanbrainproject.eu), and the Deutsche Forschung...

Orphan medicinal products (OMPs) are targeted at the diagnosis, prevention or treatment of rare diseases and have a special status in European law. This status brings incentives for pharmaceutical companies to invest in OMP development. The goal of the legislation is to encourage the development of more treatments for life-threatening rare disorders, but increased availability of OMPs raises im...

Introduction: The role of private funding in long-term care programmes (LTC) is increasing worldwide. As stated by the World Health Organisation (WHO), funding is a major tool for policy and planning. Although this is well accepted in the public sector, the policy aspects of private funding have been largely overlooked in the European countries, particularly in those with a consolidated welfare...